Clinical trials: Panuveitis
Behcet's Disease Uveitis
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
The objective of this study is to assess the efficacy and safety of gevokizumab in treating Behcet's disease uveitis (BDU).
- Trial name
- EYEGUARD™-US (NCT02258867)
- Testing
- Gevokizumab
- Where
- 8 sites in United States
- Volunteers
- 4 people
- Sponsor
- XOMA (US) LLC
Uveitis
Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
The purpose of the extension study was to provide patients completing the 28-week core study (NCT01095250) with an opportunity to receive an additional 22 weeks of continuous treatment.
- Trial name
- INSURE (NCT01103024)
- Testing
- AIN457
- Where
- 11 sites in United States, Canada and 3 more
- Sponsor
- Novartis
Behçet Disease
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease
The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to < 18 years of age with oral ulcers associated with Behçet's disease (BD)…
- Trial name
- BEAN (NCT04528082)
- Testing
- Apremilast
- Where
- 27 sites in France, Greece and 6 more
- Volunteers
- 60 people
- Sponsor
- Amgen
Non-infectious Anterior Uveitis
A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis
This is a randomized, multi-center, investigator masked, comparator controlled study. The purpose of this study is to determine the efficacy and safety of NS2 in patients with non-infectious acute anterior uveitis.
- Trial name
- NCT02406209
- Testing
- NS2, Prednisolone acetate ophthalmic suspension (1%)
- Where
- 15 sites in United States
- Volunteers
- 45 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Uveitis, Uveitis, Posterior
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert
A study to evaluate the safety and efficacy of a fluocinolone acetonide intravitreal (FAI) insert in the management of subjects with chronic non-infectious uveitis affecting the posterior segment of the eye.
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Intermediate
- Trial name
- NCT05070728
- Testing
- FAI Insert
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Non-infectious Uveitis
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression
- Trial name
- ENDURE (NCT01090310)
- Testing
- AIN457
- Where
- 35 sites in United States, Brazil and 6 more
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
This is a long-term extension trial of RAY121 in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing…
- Conditions
- Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
- Trial name
- NCT06723106
- Testing
- RAY121
- Where
- 62 sites in Australia, Austria and 17 more
- Volunteers
- 144 people
- Sponsor
- Chugai Pharmaceutical
Uveitis, Panuveitis
Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis
The purpose of this phase 3 open-labeled study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of severe uveitis.
- Trial name
- NCT00407056
- Testing
- Difluprednate Ophthalmic Emulsion
- Volunteers
- 20 people
- Sponsor
- Sirion Therapeutics, Inc.
Uveitis
Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice
This study aims at evaluating real life effectiveness of originator adalimumab (Humira®) participants with active non-infectious intermediate, posterior and panuveitis (NIIPPU) despite high-dose corticosteroid therapy; including…
- Trial name
- HOPE (NCT03155243)
- Where
- 28 sites in Austria, Colombia and 10 more
- Volunteers
- 155 people
- Sponsor
- AbbVie
Behcet Disease
A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease
The purpose of this study is to evaluate the efficacy of infliximab in induction regimen by assessing the mean decrease in Disease Activity Index for intestinal Behcet's disease (DAIBD) score of 20 or more in participants with…
- Trial name
- BEGIN (NCT02505568)
- Testing
- Infliximab
- Where
- 5 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Janssen Korea, Ltd., Korea
Uveitis
An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data
The purpose of this study is to provide continued dosing of gevokizumab in order to obtain and assess long-term gevokizumab safety data.
- Trial name
- EYEGUARD™-E (NCT02258854)
- Testing
- Dose 2 gevokizumab
- Where
- 33 sites in United States
- Volunteers
- 69 people
- Sponsor
- XOMA (US) LLC
Behcet Syndrome
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease
The purpose of this study is to assess whether Apremilast is safe and effective in the treatment of patients with Behcet Disease.
- Trial name
- NCT00866359
- Testing
- Apremilast (CC-10004)
- Where
- 7 sites in United States, Turkey (Türkiye)
- Volunteers
- 111 people
- Sponsor
- Amgen
Uveitis
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.
- Trial name
- INSURE (NCT01095250)
- Testing
- AIN457
- Where
- 36 sites in United States, Canada and 11 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Behcet Disease
Phase III Study in Refractory Behcet's Disease
The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study…
- Trial name
- SHIELD (NCT00995709)
- Testing
- AIN457
- Where
- 49 sites in United States, Egypt and 15 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Non-infectious Uveitis
Evaluation of EYS606 in Patients With Non-infectious Posterior, Intermediate or Panuveitis
Primary objective: safety and tolerability Secondary objectives: additional indicators of long term safety and indicators of clinical activity Exploratory objectives: to characterize EYS606 biodistribution, immunogenicity and…
- Trial name
- NCT03308045
- Testing
- pEYS606
- Where
- 4 sites in France, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Eyevensys
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis
A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).
- Conditions
- Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Pan Uveitis
- Trial name
- NEPTUNE (NCT05523765)
- Testing
- Brepocitinib
- Where
- 15 sites in United States
- Volunteers
- 26 people
- Sponsor
- Priovant Therapeutics, Inc.
Behçet Disease
A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group study with an equal randomization among the Hemay005 high dose, lower dose and placebo treatment groups.
- Trial name
- NCT04609397
- Testing
- Hemay005
- Where
- 31 sites in China
- Volunteers
- 89 people
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Anterior Uveitis
Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis
The purpose of this phase 2 study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of uveitis.
- Trial name
- NCT00405496
- Testing
- Difluprednate Ophthalmic Emulsion
- Volunteers
- 24 people
- Sponsor
- Sirion Therapeutics, Inc.
Behcet Syndrome, Behcet Disease
Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease
The purpose of this study is to determine the safety and efficacy of natural human interferon alpha (IFN alpha) on size, number, incidence and pain of oral ulcers associated with Behçet's Disease (BD).
- Conditions
- Behcet Syndrome, Behcet Disease, Mucocutaneous Ulceration
- Trial name
- NCT00483184
- Testing
- Veldona,
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 84 people
- Sponsor
- Nobel Pharmaceuticals
Behçet's Disease, Juvenile Psoriatic Arthritis
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
The primary objective of this study is to evaluate the long-term safety of apremilast in subjects 2 years of age or older with oral ulcers associated with Behçets disease or 5 years of age or older with active juvenile psoriatic…
- Trial name
- NCT05767047
- Testing
- Apremilast
- Where
- 7 sites in Greece, Israel and 2 more
- Volunteers
- 48 people
- Sponsor
- Amgen